1-2 of 2
Ingrid Lafon, MD
Close
Sort by
Journal Articles

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Laurent Garderet, MD PhD, Frederique Kuhnowski, MD, jean Yves Mary, MD, Murielle Roussel, Martine Escoffre-Barbe, MD, Ingrid Lafon, MD, Thierry Facon, MD, Lionel Karlin, MD, Aurore Perrot, MD, Philippe Moreau, MDPhD, Gerald Marit, MD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Carine Chaleteix, MD, Mourad Tiab, Carla Araujo, MD, Pascal Lenain, MD, Margaret Macro, MD, Eric Voog, MD, Lofti Benboubker, MD, Olivier Allangba, MD, Eric Jourdan, MD, Mohamad Mohty, MD PhD, Herve Avet Loiseau, MD PhD, Claire Mathiot, MD, Michel Attal, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 837.
https://doi.org/10.1182/blood.V130.Suppl_1.837.837
Published: 2017
Journal Articles

The 18F-FDG SUVmax Reduction After Two Cycles of R-CHOP Regimen Predicts Progression Free Survival of Patients with Diffuse Large B-Cell Lymphoma.

Rene-Olivier Casasnovas, MD, Anne Laure Saverot, MD, Alina Berriolo-Riedinger, MD, Michel Toubeau, MD, Emmanuelle Ferrant, MD, Ingrid Lafon, MD, Denis Caillot, MD, Jean-Marc Riedinger, MD, Alexandre Cochet, MD, Inna Cochet, Jean-Noël Bastie, MD, PhD, Eric Solary, MD, PhD, Francois Brunotte, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2931.
https://doi.org/10.1182/blood.V114.22.2931.2931
Published: 2009